(NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the ...

Moderna announced in October 2025 that it will discontinue development of its investigational cytomegalovirus (CMV) vaccine, ...

Moderna said its cytomegalovirus (CMV) vaccine, mRNA-1647, failed to prevent infection in women of childbearing age in a ...

Moderna (NASDAQ:MRNA) announced that its late-stage trial for the mRNA-1647 vaccine, aimed at preventing cytomegalovirus ...

A shot analysts projected as a multibillion-dollar seller produced results “well below” the company’s expectations, ...

Moderna is halting development of an mRNA vaccine for congenital cytomegalovirus after its candidate failed to protect women ...

Moderna’s highly touted cytomegalovirus vaccine — long billed as its next big win after its Covid-19 shot — failed a Phase 3 ...

Moderna said on Wednesday it would stop developing its experimental vaccine to prevent cytomegalovirus, a virus that can cause birth defects, after it failed to meet the main goal of a late-stage ...

A key question for investors going forward will be whether Moderna's other latent virus vaccines for Epstein-Barr and shingles can succeed after the failure of the CMV program.

Infection with a common virus may increase the risk of Type 2 diabetes in older adults, a new study from the Netherlands suggests. In the study, adults ages 85 and over who were infected with ...